Biotech · Private company · Durham, NC, US
Parion Sciences
Track this companyFree. Adds Parion Sciences to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- IvacaftorPhase 2 · Primary Ciliary DyskinesiaClinicalTrials.gov · fetched Nov 12, 2026
- OrkambiPhase 2 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- P-1037Phase 2 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- P-552Phase 2 · XerostomiaClinicalTrials.gov · fetched Nov 12, 2026
- VX-371Phase 2 · Primary Ciliary DyskinesiaClinicalTrials.gov · fetched Nov 12, 2026
- VX-371Phase 2 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- VX-371 + HSPhase 2 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- VX-371 + HSPhase 2 · Primary Ciliary DyskinesiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Clearing Lungs With ENaC Inhibition in Primary Ciliary DyskinesiaPHASE2 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02871778 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationPHASE2 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02709109 · fetched Nov 12, 2026
- Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)PHASE2 · COMPLETED · started Apr 1, 2015ClinicalTrials.gov NCT02343445 · fetched Nov 12, 2026
- An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal WetnessPHASE1_PHASE2 · COMPLETED · started Nov 1, 2010ClinicalTrials.gov NCT01369589 · fetched Nov 12, 2026
NIH awards2
- A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung DiseasesFiscal year 2025 · $2MNIH RePORTER 4R44HL174235-02 · fetched Nov 12, 2026
- A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung DiseasesFiscal year 2024 · $295.7KNIH RePORTER 1R44HL174235-01 · fetched Nov 12, 2026